Search Results
Your search for Caroline Helwick matches 2403 pages
Showing 201 - 250Expert Point of View: Ines Vaz-Luis, MD, PhD
The invited discussant of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, Ines Vaz-Luis, MD, PhD, of the Breast Cancer Survivorship Group, Gustave Roussy, Villejuif, France, pointed out that the benefit of ovarian suppression or ablation in reducing breast cancer...
EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
Expert Point of View: Nabil F. Saba, MD, FACP, and Jennifer Choe, MD, PhD
Nabil F. Saba, MD, FACP, Professor and Vice Chair of Hematology and Medical Oncology, the Lynne and Howard Halpern Chair in Head and Neck Cancer Research, and Director of the HNCA Medical Oncology Program at the Winship Cancer Institute, Emory University, Atlanta, was invited to discuss the...
JUPITER-02: Toripalimab Plus Chemotherapy Improved Survival Outcomes for Some Patients With Advanced Nasopharyngeal Carcinoma
In the final overall survival analysis of the phase III JUPITER-02 trial, first-line treatment with toripalimab plus gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs chemotherapy alone in...
Expert Point of View: Priyanka Bhateja, MD
Head and neck cancer specialist Priyanka Bhateja, MD, Assistant Professor in the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, was encouraged by the findings of the Quarterback trial. As she noted in her comments for The ASCO Post, human papillomavirus...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
Expert Point of View: Kathleen Moore, MD, MS
“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with The ...
In Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study Among Patients With BRCA Mutation
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
Expert Point of View: Barbara Burtness, MD
Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, featured the CONTINUUM study at the head and neck cancer session on Highlights of the Day during the 2023 ASCO Annual Meeting. She noted the study’s premise...
CONTINUUM: In Locally Advanced Nasopharyngeal Cancer, Addition of Sintilimab to Chemoradiotherapy Offers Benefit
The addition of the PD-1 inhibitor sintilimab to standard induction chemotherapy and chemoradiotherapy resulted in a significant improvement in 3-year event-free survival, a manageable safety profile, and comparable quality of life in high-risk, locally advanced nasopharyngeal carcinoma vs standard ...
Expert Point of View: Kevin Kalinsky, MD, MS
Session co-moderator Kevin Kalinsky, MD, MS, the Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director of the Glenn Family Breast Center, and Director of Breast Medical Oncology at the Winship Cancer Institute of Emory University, Atlanta, offered his thoughts on PHERGain to The...
PHERGain: Adapted-Response Trial Guides Treatment With Dual HER2 Blockade Alone
The phase II PHERGain trial, which employed a response-adapted strategy in the treatment of early-stage, HER2-positive breast cancer, has shown promising results for the selective use of HER2 blockade and de-escalation of chemotherapy.1 Nearly all patients assigned to skip chemotherapy prior to...
Expert Point of View: Erminia Massarelli, MD, PhD, MS
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
Novel HPV-Targeted Agents Boost Efficacy of Pembrolizumab in Head and Neck Cancer, Two Studies Show
Immunotherapeutics that target human papillomavirus (HPV) genotype 16 appear to boost the activity of pembrolizumab in advanced head and neck squamous cell carcinoma. Two examples were presented in posters at the 2023 ASCO Annual Meeting.1,2 The phase II VERSATILE-002 trial evaluated PDS0101,...
Expert Point of View: Caron Jacobson, MD
Caron Jacobson, MD, shared some comments on ZUMA-7 with The ASCO Post. She called ZUMA-7 “an extremely important study to advance the care of high-risk early relapsing or primary refractory large B-cell lymphoma after front-line chemoimmunotherapy.” Dr. Jacobson is Assistant Professor of Medicine...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
Lobular vs Ductal Breast Cancer: Distinctions in Management
As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...
Expert Point of View: Kohei Shitara, MD and Bradley Alexander McGregor, MD
At the ASCO session on the phase II DESTINY-PanTumor02 trial on T-DXd, the invited discussant, Kohei Shitara, MD, commented: “As expected, this trial demonstrated a very impressive response rate and duration of response” and “showed T-DXd [fam-trastuzumab deruxtecan-nxki] to be a potential new...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
Expert Point of View: Pamela L. Kunz, MD and Corrie Marijnen, MD, PhD
Commenting at a press briefing, Pamela L. Kunz, MD, Director of the Center for Gastrointestinal Cancers and Chief of GI Medical Oncology at Smilow Cancer Hospital and Yale Cancer Center, New Haven, said the results of PROSPECT are “practice-changing” and “align incredibly well with the theme at...
PROSPECT Trial: Pelvic Radiation Therapy Avoided for Most Patients With Intermediate-Risk, Locally Advanced Rectal Cancer
Patients with intermediate-risk rectal cancer who received neoadjuvant chemotherapy with selective use of pelvic chemoradiation therapy had disease-free survival that was noninferior to the standard approach using pelvic chemoradiation, according to findings from the randomized phase III PROSPECT...
DUO-O: Benefit Shown for Durvalumab Plus Olaparib in Advanced Ovarian Cancer
In newly diagnosed advanced ovarian cancer lacking a BRCA mutation, the addition of durvalumab and olaparib to standard therapy significantly improved progression-free survival, in a planned interim analysis of the international phase III DUO-O trial presented at the 2023 ASCO Annual Meeting1 and...
Expert Point of View: Chandrakanth Are, MBBS, MBA, FRCS, FACS
For comments on the phase III DIPLOMA trial, which found outcomes comparable between minimally invasive and open distal pancreatectomy, The ASCO Post interviewed Chandrakanth Are, MBBS, MBA, FRCS, FACS, the Jerald L. & Carolynn J. Varner Professor of Surgical Oncology & Global Health;...
DIPLOMA Trial: Minimally Invasive Distal Pancreatectomy Noninferior to Open Surgery for Early-Stage Pancreatic Cancer
For patients with fully resectable pancreatic cancer, a minimally invasive surgical approach—laparoscopic or robotic—was shown to be comparable to open distal pancreatectomy in the multicenter randomized phase III DIPLOMA trial. These results were presented at the 2023 ASCO Annual Meeting and at a...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Cancer Center, University of Miami, said the COMMANDS trial delivered promising results for the treatment of lower-risk myelodysplastic syndrome (MDS). “Without question, the COMMANDS study met its...
COMMANDS Trial: First-Line Luspatercept Boosts Chance of Transfusion Independence in Lower-Risk MDS
In the global phase III COMMANDS trial of patients with low-risk transfusion-dependent myelodysplastic syndrome (MDS), with or without ring sideroblasts, treatment with luspatercept essentially doubled the likelihood of achieving transfusion independence and an increase in hemoglobin level,...
Expert Point of View: Elizabeth A. Morris, MD
Elizabeth A. Morris, MD, Professor and Chair of the Department of Radiology at the University of California Davis, Sacramento, told The ASCO Post that the study by Berger et al addresses an important question. “This is a topic I am kind of passionate about—it addresses the ordering of mammograms...
Surveillance Mammography Rates After Breast Cancer Treatment Remain High, Irrespective of Life Expectancy
Is regular surveillance with mammography important in older patients with breast cancer and a shortened life expectancy? A study of 44,475 patients with breast cancer found the practice—which may yield more harms than benefits—to be common. This study is unique in that it examined surveillance...
Expert Point of View: Kathleen Moore, MD, MS
Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, spoke with The ASCO Post about GOG-258. According to Dr. Moore, the final results of this long-running...
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer
The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced endometrial cancer. After a median follow-up of 112 months, the hazard ratio for...
Expert Point of View: Sarah Blair, MD
Sarah Blair, MD, Professor and Vice Chair of the Department of Surgery at UC San Diego Health in California, offered her thoughts on the findings from these two studies. She first pointed to the growing body of data showing how nutrition and exercise programs can improve aerobic fitness, quality of ...
Exercise, Wellness Interventions in Early Breast Cancer Demonstrate Measurable Benefits—Even Economic Ones
Specialized exercise and wellness programs significantly elevated physical well-being and quality of life among patients with breast cancer while reducing the use of health-care resources in new research presented at the 2023 American Society of Breast Surgeons Annual Meeting. In one multicenter...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Novel Hormone Receptor–Driven Therapies Tackling Endocrine Resistance in Breast Cancer
In hormone receptor–positive metastatic breast cancer, tumors eventually become resistant not only to endocrine blockade but to inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6). This obstacle to successful treatment is being tackled with novel hormone receptor–directed therapies, with the...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
Elena Garralda, MD, MSc, Discusses Findings From the KRYSTAL-1 Trial
Elena Garralda, MD, MSc, Director of Early Drug Development at Vall d’Hebron University Hospital and Director of the Phase I Unit at NEXT Oncology, Barcelona, was invited to discuss the KRYSTAL-1 findings. “In KRYSTAL-1, adagrasib monotherapy has demonstrated clinically meaningful activity in a...
KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors
In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated clinical activity in previously treated patients with pancreatic ductal adenocarcinoma, biliary tract cancer, and other solid tumors harboring KRAS G12C mutations, according to research presented at the ASCO Plenary Series ...
Expert Point of View: Kathleen Moore, MD, MS
“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with...
In BRCA-Mutated Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
Expert Point of View: Kathleen Moore, MD, MS
Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, spoke with The ASCO Post about GOG-258. According to Dr. Moore, the final results of this long-running...
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer
The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced endometrial cancer. After a median follow-up of 112 months, the hazard ratio for...
KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors
In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated promising clinical activity in previously treated patients with pancreatic ductal adenocarcinoma, biliary tract cancer, and other solid tumors harboring KRAS G12C mutations, according to research presented at the April...
Emerging Success With Novel Targeted Therapies in Endocrine-Resistant Metastatic Breast Cancer
In hormone receptor–positive breast cancer, the ability to successfully target key mediators of endocrine resistance is changing the outlook of metastatic disease in this subtype, according to Aditya Bardia, MD, MPH, FASCO, Director of Breast Cancer Research and Associate Professor at Harvard...
Expert Point of View: Yelena Y. Janjigian, MD
The GLOW study’s invited discussant, Yelena Y. Janjigian, MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, said the GLOW findings are “practice-changing,” validating that high claudin-18.2 (CLDN18.2) expression as an important biomarker in...
